Sarilumab Biosimilar – Anti-IL-6R mAb – Research Grade

Reference:
Size

,

Brand

Product type

Clonality

Expression system

Description of Sarilumab Biosimilar - Anti-IL-6R mAb - Research Grade

Description of Sarilumab Biosimilar - Anti-IL-6R mAb - Research Grade

General information on Sarilumab Therapeutic Antibody

The Sarilumab antibody is a fully human IgG1 kappa monoclonal protein targeting the human interleukin 6 receptor (IL-6R). It has been generated using the VelocImmune® platform by Regeneron Pharmaceuticals Inc. which consists of immunizing engineered mice modified to produce fully human antibodies instead of murine immunoglobulins. Sarilumab was granted approval by the Food and Drug Administration (FDA) in 2017 for the treatment of rheumatoid arthritis (RA), an autoimmune condition. RA is a long-term condition affecting hands, feet, and wrists often causing tiredness and weight loss.

Sarilumab and Tocilizumab (a humanized monoclonal antibody) share the same molecular target and mechanism of action. By competitively binding the IL-6R, both antibodies are known to disrupt the pro-inflammatory response caused by the interleukin 6 (IL-9) molecule, a small soluble glycoprotein known to be overexpressed in multiple inflammatory pathologies such as the cytokine release syndrome or “cytokine storm.” Both antibodies have proved their effectiveness as monoclonal antibody therapies in vitro and the clinic.

However, recent studies have shown that Sarilumab’s in vitro binding affinity is 15-22-fold higher than that of Tocilizumab. The improved affinity also translated into a better clinical efficiency suggesting that Sarilumab is capable of effectively blocking the IL-6R with a lower dose and dosage frequency than the ones recurrently necessary in Tocilizumab-based therapies. Consequently, Sarilumab may have an overall lower cost than its humanized counterpart for the treatment of multiple diseases.

The evaluation of Sarilumab as a COVID-19 treatment is currently under regulatory revision. Prior studies with this therapeutic antibody showed a marked improvement in patients in intensive care (over 89% of patients experienced a significant improvement after receiving the antibody intravenously). However, further studies are necessary to access the efficiency and safety of the fully human therapeutic antibody for blocking IL-6R in COVID-19 patients and arrest the onset of the acute respiratory distress syndrome (ARDS) shown to contribute to significant lung damage in the most severe cases of the disease. This product is for research use only.

Product nameSarilumab Biosimilar - Anti-IL-6R mAb - Research Grade
SourceDrugBank DB11767
SpeciesHuman
Molecular weight150kDa
Purity>90%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /SynonymsSarilumab
ReferencePX-TA1028
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1Kappa
ClonalityMonoclonal Antibody
SourceDrugBank DB11767
Product nameSarilumab Biosimilar - Anti-IL-6R mAb - Research Grade
SourceDrugBank DB11767
SpeciesHuman
Expression systemMammalian cells
Molecular weight150kDa
Purity>90%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /SynonymsSarilumab
ReferencePX-TA1028
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1Kappa
ClonalityMonoclonal Antibody
SourceDrugBank DB11767

Reviews

There are no reviews yet.

Be the first to review “Sarilumab Biosimilar – Anti-IL-6R mAb – Research Grade”

Your email address will not be published.


Clear
OK

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us

Categories: